JMP keeps Boston Scientific at market perform

JMP Securities analyst Robert C. Faulkner maintained Boston Scientific Corp. at a market perform rating after The Wall Street Journal reported that an internal analysis by the company showed an increased risk of thrombosis for Taxus compared to bare-metal stents. Boston Scientific is discussing the issue with the Food and Drug Administration. Shares of the Natick, Mass.-based medical device company were down 3 cents, or 0.18%, at $16.67. (NYSE: BSX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.